Stay updated on Bortezomib vs Carfilzomib in Newly Diagnosed Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Bortezomib vs Carfilzomib in Newly Diagnosed Multiple Myeloma Clinical Trial page.

Latest updates to the Bortezomib vs Carfilzomib in Newly Diagnosed Multiple Myeloma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe site footer now identifies the ClinicalTrials.gov interface as revision v3.8.0 instead of v3.7.2. The study record content is unchanged.SummaryDifference0.1%

- Check23 days agoChange DetectedA sitewide NIH banner announces updates about a terminology transition from “Artificial Intelligence” to “Super Intelligence.”SummaryDifference0.6%

- Check29 days agoChange DetectedThe footer’s ClinicalTrials.gov revision number changed from v3.7.1 to v3.7.2.SummaryDifference0.1%

- Check37 days agoChange DetectedThe trial’s record history now includes a version submitted October 1, 2026, documenting a Study Status update. The record’s latest posted-update date is October 5, 2026.SummaryDifference0.4%

- Check57 days agoChange DetectedA new revision entry v3.7.0 has been added to the study record history, replacing the previous v3.6.6 entry. This updates the historical versioning of the record without changing the study details.SummaryDifference0.1%

- Check78 days agoChange DetectedA new revision tag v3.6.6 appears in the Record History, replacing the previous v3.6.5, signaling a minor update to the page’s release notes.SummaryDifference0.1%

Stay in the know with updates to Bortezomib vs Carfilzomib in Newly Diagnosed Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Bortezomib vs Carfilzomib in Newly Diagnosed Multiple Myeloma Clinical Trial page.